Predictive factors for response to cytotoxic treatment in advanced breast cancer: A review

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 84-90

  Sjöström, Johanna ^a   Blomqvist, Carl ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGE; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MENOPAUSE; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030483323     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083978     Document Type: Article

References (42)

1. Franco LA, Shafie SM. Estrogen receptor status, doubling time and sensitivity of breast carcinoma cells to Adriamycin in tissue culture. Proc Am Assoc Cancer Res 1981; 22: 5.
2. Swenerton K, Legha S, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Research 1979; 39: 1552-1562.
3. Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. 1986; 58: 1411-1417.
4. Kardinal C, Perry M, Korzun A, et al. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 1988; 61:415-419.
5. Gregory W, Smith P, Richards C, et al. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 1993; 68: 988-995.
6. Legha S, Buzdar A, Smith T, et al. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 1980; 46: 438-445.
7. Lippman M, Allegra J, Thompson E, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978; 298: 1223-1228.
8. Kiang D, Frenning D, Gay J, et al. Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 1980; 46: 2814-2817.
9. Jonat W, Maass H, Stolzenbach G, et al. Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 1980; 46: 2809-2813.
10. Samal B, Brooks S, Cummings G, et al. Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 1980; 46: 2925-2927.
11. Hilf R, Feldstein M, Savlov E, et al. The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 1980; 46: 2797-2800.
12. Rubens R, Hayward J. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 1980; 46: 2922-2924.
13. Rosenbaum C, Marsland T, Stolbach L, et al. Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 1980; 46: 2919-2921.
14. Corle D, Sears M, Olson K. Relationship of quantitative estrogen-receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer. Cancer 1984; 54: 1554-1561.
15. Masters J, Camplejohn R, Millis R, et al. Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. Br J Cancer 1987; 55: 455-457.
16. Niskanen E, Franssila K, Blomqvist C, et al. The prognostic role of histological grade and c-erb-B2 oncogene amplification in primary tumours of metastatic breast cancer (abstract 427). The Seventh European Conference on Clinical Oncology and Cancer Nursing, Jerusalem, 14-18 November 1993. Eur J Cancer Clin Oncol 1993; 29A (Suppl 6): 82.
17. Stuart-Harris R, Hedley D, Taylor I, et al. Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. Br J Cancer 1985; 51: 573-576.
18. Brifford M, Spyratos P, Tubiana-Hulin M, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast cancer. Cancer 1989; 63: 631-637.
19. Hietanen P, Blomqvist C, Wasenius V-M, et al. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995; 71: 1029-1032.
20. Remvikos Y, Mosseri V, Zajdela A, et al. Prognostic value of the s-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci 1993; 698: 193-203.
21. O'Reilly S, Camplejohn R, Rubens R, et al. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992; 28: 681-683.
22. Spyratos F, Brifford M, Tubiana-Hulin M, et al. Sequential Cytopunctures During Preoperative Chemotherapy for Primary Breast carcinoma. Cancer 1992; 69: 470-475.
23. Sulkes A, Livingston R, Murphy W. Tritiated thymidine labelling index and response in human breast cancer. J Natl Cancer Inst 1979; 62: 513-515.
24. Bonetti A, Sperotto L, Turazza M, et al. Tumour proliferative activity and response to first-line chemotherapy in advanced breast cancer. Proc Am Assoc Cancer Res 1994; 13: 112.
25. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic Importance of c-erb-B2 Expression in Breast Cancer. J Clin Oncol 1992; 10: 1049-1056.
26. Muss H, Thor A, Berry D, et al. c-erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
27. Wright C, Cairns J, Cantwell B, et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erb-B2 protein and glutathione s-transferases. Br J Cancer 1992; 65: 271-274.
28. Klijn J, Berns M, Bontenbal M, et al. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treatment Reviews 1993; 19 (Supplement B): 45-63.
29. Bergh J, Norberg T, Sjôgren S, et al. Sequenced based diagnosis of the complete p53 gene provides information on the response to adjuvant therapy in lymph node positive and lymph node negative breast cancer patients. Proc Am Assoc Cancer Res 1995; 14: 107.
30. Salmon S, Hamburger A, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumour stem cells to anti-cancer drugs. N Engl J Med 1978; 298: 1321-1327.
31. Twentyman P. MDR1 (P-glycoprotein) Gene expression - implications for resistance modifier trials. J Natl Cancer Inst 1992; 84: 1458-1460.
32. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111-116.
33. Ro S, Sahin A, Ro J, et al. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990; 21: 787-791.
34. Wolf R, Wareing C, Black S, et al., ed. Glutathione S-transferase in resistance to chemotherapy agents. In: Glutathione S-Transferases and drug resistance. Hayes J, Pickett C, Mantle T, eds. London: Taylor and Francis, 1990: 295.
35. Gibbs JF, Yin M-b, Toth K, et al. Role of drug concentration in adriamycin-induced apoptosis and necrosis. Proc Am Assoc Cancer Res 1994; 13: 122.
36. Krajewski S, Blomqvist C, Franssila K, et al. Reduced Expression of Proapoptotic Gene BAX Is Associated with Poor Response Rates to Combination Chemotherapy and Short Survival in Women with Metastatic Breast Adenocarcinoma. Cancer Research 1995; 55: 4471-4478.
37. George S, Hoogstraten B. Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 1978; 60: 731-736.
38. Nash C, Jones S, Moon T, et al. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 1980; 46: 2380-2388.
39. Smalley R, Lefante J, Bartolucci A. Multivariate factor analysis - advanced breast cancer chemotherapy. Proc Am Assoc Cancer Res 1981; 22: 146.
40. Hortobagyi G, Smith T, Legha S, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1: 776-786.
41. Falkson G, Gelman R, Falkson C, et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective eastern co-operative oncology group study. J Clin Oncol 1991; 9: 2153-2161.
42. Remvikos Y, Beuzeboc P, Zajdela A, et al. Correlation of pre-treatment proliferative activity of breast cancer with response to cytotoxic chemotherapy,. J Natl Cancer Inst 1989; 1: 1383-1387.